Literature DB >> 29771293

Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.

Caitlin R Rausch1, Adam J DiPippo1, Prithviraj Bose2, Dimitrios P Kontoyiannis3.   

Abstract

We retrospectively assessed breakthrough invasive fungal infections (b-IFIs) in 100 consecutive patients with leukemia receiving single-agent isavuconazole; 13 had documented b-IFIs (candidiasis in 6, mucormycosis in 4). All b-IFIs were observed in patients with prolonged neutropenia and active leukemia.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29771293      PMCID： PMC6454429          DOI： 10.1093/cid/ciy406

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

Authors:  Alexander Imhof; S Arunmozhi Balajee; David N Fredricks; Janet A Englund; Kieren A Marr
Journal:  Clin Infect Dis       Date:  2004-08-13       Impact factor: 9.079

2.  Isavuconazole: a new extended spectrum triazole for invasive mold diseases.

Authors:  Michelle R Ananda-Rajah; Dimitrios Kontoyiannis
Journal:  Future Microbiol       Date:  2015-05-21       Impact factor: 3.165

3.  Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis.

Authors:  Frederic Lamoth; Shimin J Chung; Lauro Damonti; Barbara D Alexander
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

4.  Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.

Authors:  Frank P Tverdek; Sang Taek Heo; Samuel L Aitken; Bruno Granwehr; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  Real-Life Use of Isavuconazole in Patients Intolerant to Other Azoles.

Authors:  Eloy E Ordaya; George J Alangaden
Journal:  Clin Infect Dis       Date:  2016-08-23       Impact factor: 9.079

6.  The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.

Authors:  Emily Wang; Dimitrios Farmakiotis; Daisy Yang; Deborah A McCue; Hagop M Kantarjian; Dimitrios P Kontoyiannis; Michael S Mathisen
Journal:  J Antimicrob Chemother       Date:  2015-04-07       Impact factor: 5.790

7.  Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

Authors:  Francisco M Marty; Luis Ostrosky-Zeichner; Oliver A Cornely; Kathleen M Mullane; John R Perfect; George R Thompson; George J Alangaden; Janice M Brown; David N Fredricks; Werner J Heinz; Raoul Herbrecht; Nikolai Klimko; Galina Klyasova; Johan A Maertens; Sameer R Melinkeri; Ilana Oren; Peter G Pappas; Zdeněk Ráčil; Galia Rahav; Rodrigo Santos; Stefan Schwartz; J Janne Vehreschild; Jo-Anne H Young; Ploenchan Chetchotisakd; Sutep Jaruratanasirikul; Souha S Kanj; Marc Engelhardt; Achim Kaufhold; Masanori Ito; Misun Lee; Carolyn Sasse; Rochelle M Maher; Bernhardt Zeiher; Maria J G T Vehreschild
Journal:  Lancet Infect Dis       Date:  2016-03-09       Impact factor: 25.071

8.  Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial.

Authors:  Dimitrios P Kontoyiannis; Dominik Selleslag; Kathleen Mullane; Oliver A Cornely; William Hope; Olivier Lortholary; Rodney Croos-Dabrera; Christopher Lademacher; Marc Engelhardt; Thomas F Patterson
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

9.  Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.

Authors:  Livio Pagano; Morena Caira; Anna Candoni; Franco Aversa; Carlo Castagnola; Cecilia Caramatti; Chiara Cattaneo; Mario Delia; Maria Rosaria De Paolis; Roberta Di Blasi; Luigi Di Caprio; Rosa Fanci; Mariagrazia Garzia; Bruno Martino; Lorella Melillo; Maria Enza Mitra; Gianpaolo Nadali; Annamaria Nosari; Marco Picardi; Leonardo Potenza; Prassede Salutari; Enrico Maria Trecarichi; Mario Tumbarello; Luisa Verga; Nicola Vianelli; Alessandro Busca
Journal:  Clin Infect Dis       Date:  2012-09-05       Impact factor: 9.079

10.  In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.

Authors:  Jesús Guinea; Teresa Peláez; Sandra Recio; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.938
View more
  30 in total

1.  Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.

Authors:  Xuemei Wu; Raman Venkataramanan; Ryan M Rivosecchi; Chenxiao Tang; Rachel V Marini; Ryan K Shields; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube.

Authors:  Erin K McCreary; M Hong Nguyen; Matthew R Davis; Jared Borlagdan; Ryan K Shields; Anthony D Anderson; Ryan M Rivosecchi; Rachel V Marini; Lauren M Sacha; Fernanda P Silveira; David R Andes; Alexander J Lepak
Journal:  J Antimicrob Chemother       Date:  2020-10-01       Impact factor: 5.790

Review 3.  Diagnosis and Treatment of Acute Invasive Fungal Sinusitis in Cancer and Transplant Patients.

Authors:  Monica Fung; Jennifer Babik; Ian M Humphreys; Greg E Davis
Journal:  Curr Infect Dis Rep       Date:  2019-11-26       Impact factor: 3.725

Review 4.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

5.  Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.

Authors:  Anastasia Wasylyshyn; Kathleen A Linder; Caroline G Castillo; Shiwei Zhou; Carol A Kauffman; Marisa H Miceli
Journal:  Mycopathologia       Date:  2020-01-14       Impact factor: 2.574

6.  Treatment Failure of Isavuconazole in a Patient with Cryptococcosis.

Authors:  Kathleen A Linder; Tejal N Gandhi; Marisa H Miceli
Journal:  Mycopathologia       Date:  2019-08-26       Impact factor: 2.574

7.  Preexposure to Isavuconazole Increases the Virulence of Mucorales but Not Aspergillus fumigatus in a Drosophila melanogaster Infection Model.

Authors:  Sebastian Wurster; Russell E Lewis; Nathaniel D Albert; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

8.  A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

Authors:  Anat Stern; Yiqi Su; Yeon Joo Lee; Susan Seo; Brian Shaffer; Roni Tamari; Boglarka Gyurkocza; Juliet Barker; Yael Bogler; Sergio Giralt; Miguel-Angel Perales; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-20       Impact factor: 5.742

9.  Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy.

Authors:  M Biagi; D Butler; X Tan; S Qasmieh; K Tejani; S Patel; R M Rivosecchi; M H Nguyen; C J Clancy; R K Shields; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

10.  Liquid Biopsy for Invasive Mold Infections in Hematopoietic Cell Transplant Recipients With Pneumonia Through Next-Generation Sequencing of Microbial Cell-Free DNA in Plasma.

Authors:  Joshua A Hill; Sudeb C Dalai; David K Hong; Asim A Ahmed; Carine Ho; Desiree Hollemon; Lily Blair; Joyce Maalouf; Jacob Keane-Candib; Terry Stevens-Ayers; Michael Boeckh; Timothy A Blauwkamp; Cynthia E Fisher
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.